Novartis Stock Drops 0.55% Amid Earnings Forecast Cuts and Job Reductions

Stock Performance Overview

• Opening Price: $146.59
• Highest Price: $147.28
• Lowest Price: $144.75
• Closing Price: $145.23
• Previous Close: $146.03
• Change: -$0.80
• Percentage Change: -0.55%
• Volume Traded: Approximately 3.06 million shares

On May 11, 2026, Novartis AG's stock opened at $146.59 and reached a high of $147.28, reflecting initial positive investor sentiment. However, the stock faced downward pressure throughout the day, ultimately closing at $145.23. This closing price represents a decrease from the previous trading day’s close of $146.03. The intraday trading range was relatively narrow, with a low of $144.75, indicating moderate volatility without extreme fluctuations.

Notable News and Developments

1. Earnings Forecast Adjustments: Analysts at Zacks Research lowered their earnings estimates for Novartis for the second quarter of 2026. This followed the company’s first-quarter results, which showed a slight miss on both earnings per share (EPS) and revenue forecasts. Q1 2026 results revealed net sales of $13.1 billion, down 1% reported and 5% at constant currency. EPS was $1.99, missing the consensus estimate of $2.11. These factors likely contributed to the stock’s decline as investors reacted to lowered expectations.
2. Operational Updates: Despite challenges in Q1, Novartis reaffirmed its full-year guidance, expecting net sales to grow in the low single-digit range for 2026. This reaffirmation may have provided some reassurance to investors, though it did not prevent the stock’s decline on the day.
3. Job Cuts and Site Closures: Reports surfaced that Novartis plans to cut approximately 220 jobs due to the closure of a manufacturing site in Germany. Such operational restructuring news can often generate negative investor sentiment, as it may signal cost-cutting or operational contraction.
4. Expansion Initiatives: On a positive note, Novartis announced plans to expand its manufacturing footprint in the United States, including establishing a new site in Texas. This strategy aims to enhance production capabilities and may be viewed favorably for long-term growth prospects.
5. Market Context: Broader market conditions also influenced Novartis’s stock performance. Healthcare stocks had mixed results amid ongoing economic uncertainties related to inflation and interest rates. Such external factors often impact individual stock movements.

Conclusion

Novartis AG’s stock on May 11, 2026, experienced a decline of 0.55% closing at $145.23, down from $146.03 the previous day. The stock’s intraday movement showed initial strength but was pressured downward due to a combination of lower-than-expected earnings, operational restructuring, and mixed market sentiment. Positive developments such as reaffirmed full-year guidance and U.S. manufacturing expansion were present but did not fully offset investor concerns. Going forward, investors will monitor how Novartis manages these challenges and opportunities throughout the remainder of 2026.